Table 1 Details of the antibodies, dilutions and antigen retrieval methods used in this study
Primary antibody | Dilution/incubation time | Antigen retrieval | Specificity | Source | Reference |
|---|---|---|---|---|---|
JC70 (CD31) | 1:50 (60 mina) | Protease XXIV | Endothelium | Dako, Denmark | Giatromanlaki et al16 |
ESEE 122 | 1:20 (90 mina) | MW | HIF-1α | Oxford University | Sivridis et al19 |
EP 190b | Neat (90 mina) | MW | HIF-2α | Oxford University | Sivridis et al19 |
VG1 | 1:4 (90 mina) | MW | VEGF | Oxford University | Sivridis and Giatromanlaki20 |
11B5 | 1:3 (60 mina) | MW | VEGF/KDR | Texas University | Giatromanlaki16 |
P-GF.44C | 1:4 (60 mina) | No | TP | Oxford University | Sivridis and Giatromanlaki20 |
DO-7 | 1:30 overnight at 4°C | MW | p53 | Dako | Sivridis et al21 |
124 | 1:80 overnight at 4°C | MW | bcl-2 | Dako | Sivridis et al21 |
1D5 | 1:100 (60 mina) | MW | ER | Immunon-Shandon | Sivridis et al19 |
1A6 | 1:100 (60 mina) | MW | PgR | Immunon-Shandon | Sivridis et al19 |
